A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (LYRA)
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (LYRA)
The purpose of this study is to evaluate the dose-response of bermekimab efficacy in participants with moderate to severe Hidradenitis Suppurativa (HS).
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 290 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2a/2b, Multicenter, Randomized, Placebo and Active Comparator-controlled, Double-Blind, Dose-ranging Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa
Estimated Study Start Date: September 15, 2021
Estimated Primary Completion Date: September 8, 2023
Estimated Study Completion Date: January 25, 2024
Arms:
- Placebo Comparator: Group 1: Placebo
- Active Comparator: Group 2: Adalimumab
- Experimental: Group 3: Bermekimab Dose 1
- Experimental: Group 4: Bermekimab Dose 2
- Experimental: Group 5: Bermekimab Dose 3
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 290 |
| Estimated Study start date | 15 September 2021 |
| Estimated Study Completion Date | 25 January 2024 |